New 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives. Evaluation of different moieties on the 6-aryl ring to obtain potent and selective human A2A adenosine receptor antagonists.
暂无分享,去创建一个
G. Marucci | M. Buccioni | D. Dal Ben | R. Volpini | Costanza Ceni | Aleix Martí Navia | D. Catarzi | V. Colotta | F. Varano | M. Falsini
[1] T. Choueiri,et al. Adenosine A2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. , 2019, Cancer discovery.
[2] G. Marucci,et al. Antioxidant-conjugated 1,2,4-Triazolo[4,3-a]pyrazin-3-one Derivatives: Highly Potent and Selective Human A2A Adenosine Receptor Antagonists Possessing Protective Efficacy in Neuropathic Pain. , 2019, Journal of medicinal chemistry.
[3] K. Varani,et al. Modifications on the amino-3,5-dicyanopyridine core to obtain multifaceted adenosine receptor ligands with antineuropathic activity. , 2019, Journal of medicinal chemistry.
[4] Min Zhang,et al. Inactivation of endothelial adenosine A2A receptors protects mice from cerebral ischaemia‐induced brain injury , 2019, British journal of pharmacology.
[5] G. Marucci,et al. Novel 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives as potent human adenosine A1 and A2A receptor antagonists. Evaluation of their protective effect against β-amyloid-induced neurotoxicity in SH-SY5Y cells. , 2019, Bioorganic chemistry.
[6] G. Marucci,et al. Novel human adenosine receptor antagonists based on the 7-amino-thiazolo[5,4-d]pyrimidine scaffold. Structural investigations at the 2-, 5- and 7-positions to enhance affinity and tune selectivity. , 2019, Bioorganic & medicinal chemistry letters.
[7] K. Varani,et al. Structure-activity relationship studies and pharmacological characterization of N5-heteroarylalkyl-substituted-2-(2-furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine-based derivatives as inverse agonists at human A2A adenosine receptor. , 2018, European journal of medicinal chemistry.
[8] K. Varani,et al. Identification of novel thiazolo[5,4-d]pyrimidine derivatives as human A1 and A2A adenosine receptor antagonists/inverse agonists. , 2018, Bioorganic & medicinal chemistry.
[9] Pier Andrea Borea,et al. Pharmacology of Adenosine Receptors: The State of the Art. , 2018, Physiological reviews.
[10] K. Varani,et al. The aminopyridine-3,5-dicarbonitrile core for the design of new non-nucleoside-like agonists of the human adenosine A2B receptor. , 2018, European journal of medicinal chemistry.
[11] K. Varani,et al. Inhibition of A2A Adenosine Receptor Signaling in Cancer Cells Proliferation by the Novel Antagonist TP455 , 2017, Front. Pharmacol..
[12] M. Liang,et al. Serial millisecond crystallography for routine room-temperature structure determination at synchrotrons , 2017, Nature Communications.
[13] A. Cavalli,et al. The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A2A Receptor Subtype. , 2017, Journal of medicinal chemistry.
[14] F. Cayabyab,et al. Adenosine A1 and A2A Receptors in the Brain: Current Research and Their Role in Neurodegeneration , 2017, Molecules.
[15] M. Sturlese,et al. The role of 5-arylalkylamino- and 5-piperazino- moieties on the 7-aminopyrazolo[4,3-d]pyrimidine core in affecting adenosine A1 and A2A receptor affinity and selectivity profiles , 2017, Journal of enzyme inhibition and medicinal chemistry.
[16] K. Varani,et al. Design, Synthesis, and Pharmacological Characterization of 2-(2-Furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine Derivatives: New Highly Potent A2A Adenosine Receptor Inverse Agonists with Antinociceptive Activity. , 2016, Journal of medicinal chemistry.
[17] P. Darcy,et al. Immunosuppressive activities of adenosine in cancer. , 2016, Current opinion in pharmacology.
[18] K. Varani,et al. Adenosine as a Multi-Signalling Guardian Angel in Human Diseases: When, Where and How Does it Exert its Protective Effects? , 2016, Trends in pharmacological sciences.
[19] A. Abdel‐Rahman,et al. Role of adenosine A2A receptor in cerebral ischemia reperfusion injury: Signaling to phosphorylated extracellular signal-regulated protein kinase (pERK1/2) , 2016, Neuroscience.
[20] F. Pedata,et al. Adenosine A2A Receptors Modulate Acute Injury and Neuroinflammation in Brain Ischemia , 2014, Mediators of inflammation.
[21] R. Cunha,et al. Role of Microglia Adenosine A2A Receptors in Retinal and Brain Neurodegenerative Diseases , 2014, Mediators of inflammation.
[22] L. Antonioli,et al. Immunity, inflammation and cancer: a leading role for adenosine , 2013, Nature Reviews Cancer.
[23] M. Smyth,et al. Extracellular adenosine triphosphate and adenosine in cancer , 2010, Oncogene.
[24] P Willett,et al. Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.